Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma

(2018) Xiaofang Guo et al.   Translational Oncology

Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis

(2018) Xin Huang et al.   Journal of Cancer

Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma

(2018) Kyu Seo Kim et al.   OncoImmunology

PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival

(2017) Cristina Alessi et al.   MELANOMA RESEARCH

The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis

(2017) Y. Ding et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

(2017) Xinxin Zhu et al.   Oncotarget

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

(2016) Junzo Hamanishi et al.   International Journal of Clinical Oncology

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer

(2016) Adrian G. Sacher et al.   JAMA Oncology

PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises

(2015) F. Massari et al.   CANCER TREATMENT REVIEWS

Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

(2011) X. Frigola et al.   CLINICAL CANCER RESEARCH

Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines

(2011) Yongjing Chen et al.   CYTOKINE